Cyclopharm Limited
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a CYC.AX research report →
Price Chart
About the company
Cyclopharm Limited is an international enterprise specializing in the production and global distribution of medical devices and radiopharmaceuticals, with operations spanning Asia Pacific, Europe, Canada, and other regions. The company's business activities are structured into two principal divisions: Technegas and Molecular Imaging. Through its Technegas segment, Cyclopharm supplies diagnostic apparatus and accompanying consumables critical for clinicians in the identification of pulmonary embolisms, alongside distributing third-party offerings to the broader diagnostic imaging sector.
- CEO
- James S. McBrayer BSPharm
- IPO
- 2007
- Employees
- 109
- HQ
- Kingsgrove, NSW, AU
Get TickerSpark's AI analysis on CYC.AX
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $62.24M
- P/E
- -3.17
- PEG
- 0.11
- P/S
- 1.93
- P/B
- 2.01
- EV/EBITDA
- -4.30
- Div Yield
- 0.00%
- Gross Margin
- 24.11%
- Op Margin
- -56.36%
- Net Margin
- -53.27%
- ROE
- -54.48%
- ROIC
- -50.65%
Latest fiscal year · YoY change
- Revenue
- $32.33M+17.2%
- Gross Profit
- $-1,459,249-108.1%
- Op Income
- $-18,182,365
- Net Income
- $-17,219,906-30.5%
- EPS
- $-0.16-23.1%
- OCF Growth
- -37.8%
- FCF Growth
- -42.6%
- 52W High
- $1.29
- 52W Low
- $0.45
- 50D MA
- $0.53
- 200D MA
- $0.76
- Beta
- 0.59
- RSI (14)
- 42
- Avg Volume
- 153.13K
No earnings-call transcripts are available for CYC.AX yet.
- Free Float
- 51.4%
- Shares Outstanding
- 125.73M
- Float Shares
- 64.64M
Our CYC.AX coverage
Recent articles, reports, and earnings notes.
No research on CYC.AX yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate CYC.AX report →